Hubbry Logo
Ryanodine receptorRyanodine receptorMain
Open search
Ryanodine receptor
Community hub
Ryanodine receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ryanodine receptor
Ryanodine receptor
Ryanodine receptor
View on Wikipedia
from Wikipedia

Cytoplasmic face of phosphorylated RyR2 in open conformation. PDB: 7U9R​

Ryanodine receptors (RyR) make up a class of high-conductance, intracellular calcium channels present in various forms, such as animal muscles and neurons.[1] There are three major isoforms of the ryanodine receptor, which are found in different tissues and participate in various signaling pathways involving calcium release from intracellular organelles.[2]

Ryanodine

Structure

[edit]

Ryanodine receptors are multidomain homotetramers which regulate intracellular calcium ion release from the sarcoplasmic and endoplasmic reticula.[3] They are the largest known ion channels, with weights exceeding 2 megadaltons, and their structural complexity enables a wide variety of allosteric regulation mechanisms.[4][5]

RyR1 cryo-EM structure revealed a large cytosolic assembly built on an extended α-solenoid scaffold connecting key regulatory domains to the pore. The RyR1 pore architecture shares the general structure of the six-transmembrane ion channel superfamily. A unique domain inserted between the second and third transmembrane helices interacts intimately with paired EF-hands originating from the α-solenoid scaffold, suggesting a mechanism for channel gating by Ca2+.[1][6]

Etymology

[edit]

The ryanodine receptors are named after the plant alkaloid ryanodine which shows a high affinity to them.

Isoforms

[edit]

There are multiple isoforms of ryanodine receptors:

Non-mammalian vertebrates typically express two RyR isoforms, referred to as RyR-alpha and RyR-beta. Many invertebrates, including the model organisms Drosophila melanogaster (fruitfly) and Caenorhabditis elegans, only have a single isoform. In non-metazoan species, calcium-release channels with sequence homology to RyRs can be found, but they are shorter than the mammalian ones and may be closer to inositol trisphosphate (IP3) receptors.

ryanodine receptor 1 (skeletal)
Identifiers
SymbolRYR1
Alt. symbolsMHS, MHS1, CCO
NCBI gene6261
HGNC10483
OMIM180901
RefSeqNM_000540
UniProtP21817
Other data
LocusChr. 19 q13.1
Search for
StructuresSwiss-model
DomainsInterPro
ryanodine receptor 2 (cardiac)
Identifiers
SymbolRYR2
NCBI gene6262
HGNC10484
OMIM180902
RefSeqNM_001035
UniProtQ92736
Other data
LocusChr. 1 q42.1-q43
Search for
StructuresSwiss-model
DomainsInterPro
ryanodine receptor 3
Identifiers
SymbolRYR3
NCBI gene6263
HGNC10485
OMIM180903
RefSeqNM_001036
UniProtQ15413
Other data
LocusChr. 15 q14-q15
Search for
StructuresSwiss-model
DomainsInterPro

Physiology

[edit]

Ryanodine receptors mediate the release of calcium ions from the sarcoplasmic reticulum and endoplasmic reticulum, an essential step in muscle contraction.[1] In skeletal muscle, activation of ryanodine receptors occurs via a physical coupling to the dihydropyridine receptor (a voltage-dependent, L-type calcium channel), whereas in cardiac muscle, the primary mechanism of activation is calcium-induced calcium release, which causes calcium outflow from the sarcoplasmic reticulum.[9]

It has been shown that calcium release from a number of ryanodine receptors in a RyR cluster results in a spatiotemporally-restricted rise in cytosolic calcium that can be visualized as a calcium spark.[10] Calcium release from RyR has been shown to regulate ATP production in heart and pancreas cells.[11][12][13]

Ryanodine receptors are similar to the inositol trisphosphate (IP3 or InsP3) receptor, and stimulated to transport Ca2+ into the cytosol by recognizing Ca2+ on its cytosolic side, thus establishing a positive feedback mechanism; a small amount of Ca2+ in the cytosol near the receptor will cause it to release even more Ca2+ (calcium-induced calcium release/CICR).[1] However, as the concentration of intracellular Ca2+ rises, this can trigger closing of RyR, preventing the total depletion of SR. This finding indicates that a plot of opening probability for RyR as a function of Ca2+ concentration is a bell-curve.[14] Furthermore, RyR can sense the Ca2+ concentration inside the ER/SR and spontaneously open in a process known as store overload-induced calcium release (SOICR).[15]

RyRs are especially important in neurons and muscle cells. In heart and pancreas cells, another second messenger (cyclic ADP-ribose) takes part in the receptor activation.

The localized and time-limited activity of Ca2+ in the cytosol is also called a Ca2+ wave. The propagation of the wave is accomplished by the feedback mechanism of the ryanodine receptor. The activation of phospholipase C by GPCR or RTK triggers the production of inositol trisphosphate, which activates of the InsP3 receptor.

Pharmacology

[edit]
  • Antagonists:[16]
  • Activators:[17]
    • Agonist: 4-chloro-m-cresol and suramin are direct agonists, i.e., direct activators.
    • Xanthines like caffeine and pentifylline activate it by potentiating sensitivity to native ligand Ca.
    • Physiological agonist: Cyclic ADP-ribose can act as a physiological gating agent. It has been suggested that it may act by making FKBP12.6 (12.6 kilodalton FK506 binding protein, as opposed to 12 kDa FKBP12 which binds to RyR1) which normally bind (and blocks) RyR2 channel tetramer in an average stoichiometry of 3.6, to fall off RyR2 (which is the predominant RyR in pancreatic beta cells, cardiomyocytes and smooth muscles).[18]

A variety of other molecules may interact with and regulate ryanodine receptor. For example: dimerized Homer physical tether linking inositol trisphosphate receptors (IP3R) and ryanodine receptors on the intracellular calcium stores with cell surface group 1 metabotropic glutamate receptors and the Alpha-1D adrenergic receptor[19]

Ryanodine

[edit]

The plant alkaloid ryanodine, for which this receptor was named, has become an invaluable investigative tool. It can block the phasic release of calcium, but at low doses may not block the tonic cumulative calcium release. The binding of ryanodine to RyRs is use-dependent, that is the channels have to be in the activated state. At low (<10 micromolar, works even at nanomolar) concentrations, ryanodine binding locks the RyRs into a long-lived subconductance (half-open) state and eventually depletes the store, while higher (~100 micromolar) concentrations irreversibly inhibit channel-opening.

Diamide insecticide

[edit]

The diamides, an important class of insecticide making up 13% of the insecticide market,[20] work by activating insect RyRs.[21]

Associated proteins

[edit]

RyRs form docking platforms for a multitude of proteins and small molecule ligands.[1] Accessory proteins bind these channels and regulate their gating, localization, expression, and integration with cellular signaling in a tissue- and isoform-specific manner.

FK506-Binding Proteins (FKBP12 / FKBP12.6) — aka Calstabin-1 and Calstabin-2 — stabilize the closed state of RyRs, preventing pathological Ca²⁺ leak.[8]

The cardiac-specific isoform (RyR2) is known to form a quaternary complex with luminal calsequestrin, junctin, and triadin.[22] Calsequestrin (CASQ) has multiple Ca2+ binding sites that bind with very low affinity, allowing easy ion release. It acts as RyR gate modulators by signaling when Ca2+ stores are full. Triadin and Junctin are sarcoplasmic reticulum (SR) membrane proteins that link RyRs to CASQ and also respond to Ca²⁺ store levels.[23]

Calmodulin (CaM) and S100A1 both bind the same site on RyRs (especially RyR1 and RyR2), but exert opposite effects: Ca²⁺-bound CaM inhibits RyRs while S100A1 enhances its opening. Expression levels and competition between these proteins tune RyR responses to Ca²⁺ signals.[8]


Role in disease

[edit]

RyR1 mutations are associated with malignant hyperthermia and central core disease.[24] Mutant-type RyR1 receptors exposed to volatile anesthetics or other triggering agents can display an increased affinity for cytoplasmic Ca2+ at activating sites as well as a decreased cytoplasmic Ca2+ affinity at inhibitory sites.[25] The breakdown of this feedback mechanism causes uncontrolled release of Ca2+ into the cytoplasm, and increased ATP hydrolysis resulting from ATPase enzymes shuttling Ca2+ back into the sarcoplasmic reticulum leads to excessive heat generation.[26]

RyR2 mutations play a role in stress-induced polymorphic ventricular tachycardia (a form of cardiac arrhythmia) and ARVD.[7] It has also been shown that levels of type RyR3 are greatly increased in PC12 cells overexpressing mutant human Presenilin 1, and in brain tissue in knockin mice that express mutant Presenilin 1 at normal levels,[27] and thus may play a role in the pathogenesis of neurodegenerative diseases, like Alzheimer's disease.[28]

The presence of antibodies against ryanodine receptors in blood serum has also been associated with myasthenia gravis (i.e., MG).[1] Individuals with MG who have antibodies directed against ryanodine receptors typically have a more severe form of generalized MG in which their skeletal muscle weaknesses involve muscles that govern basic life functions.[29]

Sudden cardiac death in several young individuals in the Amish community (four of which were from the same family) was traced to homozygous duplication of a mutant RyR2 (Ryanodine Receptor) gene.[30] Normal (wild type) ryanodine receptors are involved in CICR in heart and other muscles, and RyR2 functions primarily in the myocardium (heart muscle).

As potential drug targets

[edit]

The expression, distribution, and gating of RyRs are modified by cellular proteins, presenting an opportunity to develop new drugs that target RyR channel complexes by manipulating these proteins. Several drugs, such as FK506, rapamycin, and K201, can modify interactions between RyRs and their accessory proteins.[8]

Drug Target Effect Clinical Use Concerns
FK506, Rapamycin FKBP-RyR Disrupts complex, causes leak Immunosuppressant Not RyR-specific
K201 (JTV519) FKBP-RyR Stabilizes complex, prevents leak Heart Failure (still investigational) Off-target SERCA inhibition
Dantrolene RyR1, RyR3 receptor antagonist MH, spasticity No effect on RyR2
Doxorubicin, Tricyclic antidepressants CASQ2 Reduces Ca²⁺ buffering Chemotherapy, antidepressants Cardiotoxicity
Ivabradine Unknown Increases FKBP12/12.6 levels Heart Failure (bradycardia) Indirect mechanistic action
Statins RyR3 upregulation Myopathy Hypercholesterolemia Adverse skeletal muscle effects

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ryanodine receptor

View on Grokipedia
from Grokipedia
The ryanodine receptor (RyR) is a family of large homotetrameric intracellular calcium release channels embedded in the membranes of the sarcoplasmic reticulum (SR) in muscle cells and the endoplasmic reticulum (ER) in other cell types, playing a central role in calcium signaling by releasing stored Ca²⁺ ions into the cytoplasm to trigger processes such as muscle contraction, neurotransmitter release, and gene expression. Named after the plant alkaloid ryanodine, which binds to these channels with high affinity, RyRs were first purified and characterized in the late 1980s from skeletal muscle SR, where they were identified as the functional counterpart to the foot structures observed in electron microscopy. Each RyR tetramer, weighing approximately 2.2–2.3 MDa, consists of four identical subunits of over 500 kDa, featuring an extensive cytoplasmic domain for modulator binding and a transmembrane region forming the selective Ca²⁺-permeable pore. Three principal isoforms exist in mammals—RyR1, RyR2, and RyR3—encoded by distinct genes (RYR1 on chromosome 19q13.2, RYR2 on 1q43, and RYR3 on 15q15.2) and sharing about 65–70% sequence identity, with tissue-specific expression patterns that dictate their physiological roles. RyR1 predominates in skeletal muscle, where it facilitates excitation-contraction coupling through direct physical interaction with dihydropyridine receptors (DHPRs) in the plasma membrane, enabling voltage-sensing to trigger Ca²⁺ release without requiring initial Ca²⁺ influx. In contrast, RyR2 is the primary isoform in cardiac muscle and certain neurons, supporting Ca²⁺-induced Ca²⁺ release (CICR) amplified by small Ca²⁺ entry through L-type channels during action potentials. RyR3, expressed more broadly in brain, smooth muscle, epithelial cells, and some skeletal muscles (e.g., diaphragm), exhibits intermediate properties and may modulate Ca²⁺ signaling in non-excitable tissues or fine-tune release in excitable ones, though its precise functions remain under investigation. RyRs are tightly regulated by cytosolic and luminal Ca²⁺ levels, adenine nucleotides like ATP, divalent cations such as Mg²⁺, and accessory proteins including FKBP12/12.6 (which stabilize the closed state) and calmodulin, with phosphorylation by kinases like PKA altering channel gating and contributing to diseases when dysregulated. Mutations in RyR1 cause disorders such as malignant hyperthermia and central core disease, while RyR2 variants are implicated in catecholaminergic polymorphic ventricular tachycardia (CPVT) and heart failure through "leaky" channels that deplete SR Ca²⁺ stores and promote arrhythmias. Ongoing research highlights therapeutic potential in stabilizing RyRs with compounds like dantrolene (for RyR1-related conditions) or Rycals (for RyR2 leaks), underscoring their biomedical significance beyond basic physiology.

Discovery and Nomenclature

Historical Discovery

The discovery of the ryanodine receptor (RyR) as a calcium release channel emerged from pharmacological studies in the late 1960s and 1970s, which highlighted ryanodine's potent effects on skeletal muscle contraction. In frog skeletal muscle preparations, ryanodine was observed to induce sustained contractures or inhibit relaxation by altering intracellular calcium dynamics, suggesting interference with sarcoplasmic reticulum (SR) calcium handling mechanisms central to excitation-contraction (EC) coupling. These findings built on earlier work showing ryanodine's dose-dependent modulation of twitch tension and caffeine potentiation, providing early evidence that it targeted SR calcium release pathways essential for muscle activation. A pivotal structural milestone came in 1975 when electron microscopy studies by Franzini-Armstrong revealed "foot" structures—square-shaped assemblies spanning the gap between T-tubules and SR terminal cisternae in skeletal muscle triads. These feet, approximately 20-30 nm in size and arranged in tetragonal arrays, were hypothesized to mediate physical and functional links in EC coupling, later confirmed as the cytoplasmic domains of RyRs. In the 1980s, biochemical advances enabled purification of the RyR as a high-molecular-weight protein complex from rabbit skeletal muscle SR. Imagawa et al. (1987) isolated the RyR using ryanodine affinity chromatography, identifying it as a ~450 kDa polypeptide that formed the Ca²⁺-permeable pore of the SR release channel, with morphology matching the foot structures observed via electron microscopy. This purification facilitated the cloning of RyR1 cDNA by Takeshima et al. (1989), who sequenced the full 5037-amino-acid structure from rabbit skeletal muscle, establishing RyR1 as the primary isoform in skeletal tissue and confirming its role in voltage-dependent calcium release during EC coupling. Functional characterization advanced in the late 1980s and 1990s through reconstitution experiments in planar lipid bilayers. Lai et al. (1988) demonstrated that purified skeletal muscle RyR formed large-conductance (~100 pS) cation channels selective for Ca²⁺, modulated by ryanodine, ATP, and micromolar Ca²⁺ concentrations, directly verifying its activity as the SR Ca²⁺ release channel. These studies solidified the link between RyR and EC coupling, as ryanodine's blockade of channel activity depleted SR Ca²⁺ stores and abolished contraction, underscoring the receptor's indispensable role in skeletal muscle physiology.

Etymology

The name "ryanodine receptor" originates from ryanodine, a diterpenoid extracted from the stems of the South American shrub Ryania speciosa (), which was first isolated in 1948 by Folkers and colleagues and employed as an insecticide due to its potent toxicity toward insects. The genus Ryania itself was established in 1796 by Danish botanist Martin Vahl to honor John Ryan, an Irish physician and plant collector who supplied Vahl with specimens from tropical regions. The suffix "receptor" denotes the protein's identification as a high-affinity binding site for ryanodine, first demonstrated in the 1970s through studies on isolated membranes from , where the alkaloid's effects on calcium fluxes revealed its interaction with this intracellular structure. This binding facilitated the purification and characterization of the protein as the primary calcium release channel in muscle cells. In scientific literature, the ryanodine receptor is also known by alternative designations such as Ca²⁺ release channel (CRC) or intracellular Ca²⁺ release channel (ICRC), reflecting its functional role in mediating calcium efflux from intracellular stores.

Molecular Structure

Overall Architecture

The ryanodine receptor (RyR) is a homotetrameric ion channel complex composed of four identical monomers, each with a molecular mass of approximately 565 kDa, resulting in a total channel mass of about 2.2 MDa. This massive assembly spans the sarcoplasmic or endoplasmic reticulum membrane, facilitating calcium release into the cytosol. The overall topology resembles a mushroom, with a narrow transmembrane domain (TMD) serving as the "stem" that embeds in the lipid bilayer and forms the ion-conducting pore, while the expansive cytoplasmic domain (CPD) acts as the "cap," comprising roughly 90% of the total mass and extending prominently into the cytoplasm. The TMD consists of a bundle of transmembrane helices, including a characteristic six-transmembrane (6-TM) architecture per monomer that lines the central ion pathway, with the S6 helices extending into the cytoplasm to form inner branches. In contrast, the CPD forms a large, flat square prism approximately 275 × 275 × 120 Å in dimensions, housing multiple subdomains that contribute to the receptor's regulatory complexity. The foot domain, a prominent protrusion of the CPD, extends into the cytosol and is positioned to interact with voltage-sensing dihydropyridine receptors in skeletal muscle, bridging the gap between the T-tubule and sarcoplasmic reticulum membranes. Advances in cryogenic electron microscopy (cryo-EM) during the 2010s and 2020s have resolved the RyR structure at near-atomic resolutions of 3–4 Å, enabling visualization of secondary structures such as α-helices and side chains. These studies reveal a strict four-fold (C4) symmetry around the central axis, with a wide central vestibule in the CPD formed by the N-terminal domains that accommodates ion transit and regulatory elements. Early cryo-EM maps from the 2010s confirmed the tetrameric assembly and gross morphology, while later refinements in lipid-embedded states achieved resolutions as high as 3.4 Å, highlighting conformational dynamics without altering the core architectural features.

Functional Domains

The ryanodine receptor (RyR) is a homotetrameric with distinct functional domains that contribute to its calcium release function, primarily through structural modules that facilitate ion handling, subunit coordination, and modulator interactions. These domains span the large cytoplasmic assembly and the membrane-spanning regions, enabling coordinated gating and selective permeation. Cryo-EM and crystallographic studies have delineated these modules, revealing their roles in maintaining channel integrity and responsiveness. The N-terminal region of RyR encompasses three hotspot domains (domains 1-3, approximately residues 1-614), which serve as critical sites for Ca²⁺ binding and channel gating. These domains form a compact with three subdomains connected by a central that stabilizes positive charges, allowing allosteric transmission of Ca²⁺ signals to influence pore opening. Mutations in these hotspots, such as those linked to and central core , disrupt Ca²⁺ sensitivity and inter-domain communications, underscoring their role in gating control. In the central cytoplasmic domain, four repeat domains, organized as tandem pairs Repeat12 (residues ~850–1050) and Repeat34 (residues ~2735–2938, RyR1 numbering), mediate inter-subunit interactions essential for tetrameric stability and conformational coupling across the channel. These armadillo-like repeats form a scaffold that supports long-range allostery, with structural elements like the U-lid in Repeat12 facilitating subunit contacts in the 2D lattice arrangement. Adjacent SPRY domains (e.g., SPRY1, residues 650-844) function as protein-protein interaction hubs, binding regulatory proteins such as FKBP12/12.6 through specific loops and β-hairpin motifs, which modulate channel stability without directly altering permeation. Disease mutations in these regions, like N760D in SPRY1, impair binding and folding, leading to dysfunctional gating. The pore-forming (TMD), comprising six transmembrane helices per subunit (S1-S6) in the C-terminal quarter (residues ~4300-5000), houses the selectivity filter that permits high-conductance Ca²⁺ at rates of 100-500 pS under physiological conditions. Key negatively charged residues, such as Asp4899 and Glu4900 in the filter region (near the conserved GIGD motif), create an electrostatic environment that favors divalent cation selectivity over monovalents, enabling rapid Ca²⁺ efflux while excluding other ions. This architecture ensures efficient ion flow during release events, with the filter accommodating multiple cations simultaneously in open states. The C-terminal domain, extending beyond the TMD (residues ~4900-5037 in RyR1), coordinates ion permeation and serves as the primary binding site for ryanodine, the namesake ligand that locks the channel in subconductive states. This domain includes a pseudosymmetric bundle that aligns the pore for selective Ca²⁺ passage and harbors sites for ryanodine interaction near the selectivity filter, influencing conductance modulation. Structural analyses confirm that ryanodine binding stabilizes an open-like conformation at low affinity or closed at high affinity, highlighting the domain's role in fine-tuning permeation dynamics.

Isoforms and Expression

RyR1

The RyR1 isoform is encoded by the RYR1 gene, located on chromosome 19q13.2, and spans 106 exons, producing a transcript of approximately 15 kb that translates into a large protein of about 565 kDa. This isoform is the predominant ryanodine receptor in mammalian skeletal muscle, where it localizes primarily to the sarcoplasmic reticulum (SR) membrane, forming homotetrameric channels essential for calcium handling. Unlike RyR2 and RyR3, which have broader tissue distributions, RyR1 is primarily expressed in skeletal muscle, with low levels in other tissues including the brain and smooth muscle. In terms of expression patterns, RyR1 accounts for the vast majority of total ryanodine receptors in adult fast-twitch skeletal muscle fibers, comprising over 95% of the isoform pool based on ryanodine binding and immunoprecipitation assays in murine models. This dominance supports efficient calcium release in high-force contraction scenarios typical of fast-twitch fibers. In contrast, RyR1 levels are notably lower in embryonic skeletal muscle and slow-twitch fibers, where RyR3 expression is relatively higher (up to 10-15% of total RyRs in early development), reflecting a developmental shift toward RyR1 predominance as muscle maturation progresses. These patterns ensure adaptive calcium signaling during muscle growth and fiber-type specialization.

RyR2

The RyR2 isoform is encoded by the RYR2 gene, located on chromosome 1q43. This isoform predominates in the sarcoplasmic reticulum (SR) of cardiac muscle and is also prominently expressed in smooth muscle tissues. In cardiomyocytes, RyR2 constitutes the vast majority of ryanodine receptor expression, enabling its central role in cardiac calcium handling. Beyond muscle, RyR2 shows high expression in the hippocampus and Purkinje cells of the cerebellum and cerebral cortex.

RyR3

The RyR3 isoform is encoded by the RYR3 gene, located on the long arm of human at the 15q13.3-q14 locus. This gene produces a protein that functions as a calcium release channel in the , similar to other ryanodine receptor isoforms, but with a more ubiquitous yet low-abundance expression profile. Like RyR1 and RyR2, RyR3 assembles into a homotetrameric structure, forming a large complex essential for intracellular calcium . RyR3 expression is notably low in most adult tissues but prominent in specific regions, including the brain (particularly the cerebellum, hippocampus, caudate nucleus, and amygdala), smooth muscle, and developing skeletal muscle. In skeletal muscle, it is co-expressed with RyR1 during embryonic and early postnatal development, as well as in the diaphragm, where levels remain relatively higher into adulthood compared to other fast-twitch muscles. This pattern suggests a supportive role in tissues undergoing maturation or mixed fiber types, rather than dominance in fully differentiated contractile systems. Recent cryo-EM studies as of 2024 have revealed that RyR3 maintains a high intrinsic open probability under activating conditions (e.g., 30 µM Ca²⁺ with ATP and caffeine), with conformational shifts in the N-terminal and transmembrane domains facilitating channel opening, highlighting its distinct gating properties.

Physiological Roles

In Skeletal Muscle

In skeletal muscle, the ryanodine receptor type 1 (RyR1), the predominant isoform expressed in this tissue, plays a central role in excitation-contraction (EC) coupling by mediating the rapid release of calcium ions (Ca²⁺) from the sarcoplasmic reticulum (SR) in response to membrane depolarization. This process begins when an action potential propagates along the surface membrane and into the transverse tubules (t-tubules), causing conformational changes in the dihydropyridine receptor (DHPR), a voltage-gated L-type calcium channel complex located in the t-tubule membrane. Unlike in cardiac muscle, skeletal muscle EC coupling does not rely on Ca²⁺ influx through DHPR; instead, RyR1 is directly physically coupled to DHPR within the triad junctions, where t-tubules invaginate and appose the SR membrane. This juxtaposition allows DHPR to act as a voltage sensor that mechanically gates RyR1, triggering synchronized opening of RyR1 channels without requiring intermediate Ca²⁺ signals. The direct coupling ensures highly efficient and uniform Ca²⁺ release across the fiber, with each calcium release unit (CRU)—comprising arrays of RyR1 tetramers opposite DHPR tetrads—contributing to the rapid Ca²⁺ flux during peak activation. This flux elevates cytosolic Ca²⁺ concentration from resting levels of ~100 nM to ~10 μM within milliseconds, enabling binding to troponin C and initiating actin-myosin cross-bridge cycling for contraction. Following release, SR Ca²⁺ stores are rapidly refilled by sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pumps, which actively transport Ca²⁺ back into the SR against its concentration gradient using ATP hydrolysis, restoring the stores for subsequent contractions. Prolonged muscle activity, such as during intense exercise, can lead to RyR1 uncoupling from DHPR and increased Ca²⁺ leak through RyR1 channels, contributing to muscle fatigue by reducing the efficiency of EC coupling and elevating resting cytosolic Ca²⁺ levels. This uncoupling is often associated with post-translational modifications of RyR1, such as oxidation or phosphorylation, which destabilize the closed state of the channel and promote diastolic leak, ultimately impairing force generation and accelerating fatigue onset. Species variations in RyR1-mediated Ca²⁺ release highlight differences in EC coupling architecture: in mammalian skeletal muscle, release is predominantly junctional, tightly confined to triad sites for precise spatial control, whereas in amphibian (e.g., frog) muscle, it includes both junctional and parajunctional components, allowing broader Ca²⁺ diffusion and potentially slower kinetics due to less organized CRUs. These distinctions arise from evolutionary adaptations in SR-t-tubule organization and RyR isoform distribution, with amphibians expressing multiple RyR types that support parajunctional release.

In Cardiac Muscle

In cardiac muscle, the ryanodine receptor isoform RyR2 serves as the primary mediator of excitation-contraction coupling through calcium-induced calcium release (CICR). Action potentials depolarize the sarcolemma, opening L-type voltage-gated Ca²⁺ channels (Cav1.2) to permit a small influx of extracellular Ca²⁺, which binds to and activates RyR2 channels clustered in the sarcoplasmic reticulum (SR) membrane at dyadic junctions. This trigger Ca²⁺ influx locally elevates cytosolic Ca²⁺ concentration to approximately 10 μM, inducing cooperative opening of RyR2 and massive Ca²⁺ efflux from the SR—amplifying the signal by 10- to 100-fold to reach levels sufficient (around 1-10 μM) for binding troponin C and driving myofilament cross-bridge cycling for contraction. The spatiotemporal dynamics of RyR2-mediated release underpin both normal and aberrant Ca²⁺ signaling in cardiomyocytes. At the subcellular level, elementary release events called Ca²⁺ sparks arise from stochastic, synchronized openings of 4-20 RyR2 channels within a couplon, producing transient, localized Ca²⁺ elevations (peak amplitude ~300-500 nM, duration ~50 ms, spatial spread ~1-2 μm) that serve as building blocks for global Ca²⁺ transients during systole. Under conditions of high SR Ca²⁺ load or elevated cytosolic Ca²⁺, regenerative propagation of sparks can form traveling Ca²⁺ waves, which synchronize release across the cell but also contribute to proarrhythmic activity if uncontrolled. Diastolic Ca²⁺ leak through partially open RyR2 channels, occurring at rates up to 2-5% of systolic release, depletes SR stores and generates Ca²⁺ waves that activate the Na⁺/Ca²⁺ exchanger to produce delayed afterdepolarizations, thereby predisposing to triggered arrhythmias such as ventricular tachycardia. RyR2 function adapts to physiological demands through reversible phosphorylation, which modulates CICR gain and ensures robust contractility. During β-adrenergic stimulation, such as in the fight-or-flight response, protein kinase A (PKA) phosphorylates RyR2 at serine 2030, increasing channel open probability and enhancing Ca²⁺ sensitivity, thereby amplifying SR Ca²⁺ release to boost systolic Ca²⁺ transients and force generation without excessively prolonging release duration. This tuning is counterbalanced by phosphatases like PP1, maintaining homeostasis under basal conditions. In heart failure, RyR2 diastolic leak is primarily associated with post-translational modifications such as oxidation and S-nitrosylation, which destabilize the channel and compromise Ca²⁺ handling, rather than PKA hyperphosphorylation.

In Non-Muscle Tissues

Ryanodine receptors (RyRs) play critical roles in within neuronal tissues, particularly in the hippocampus where RyR2 and RyR3 isoforms facilitate and [long-term potentiation](/page/Long-term_p potentiation) (LTP). In hippocampal neurons, stimulation induces RyR2-mediated Ca²⁺ release from the (ER), contributing to nuclear Ca²⁺ signals that support neuronal activity-dependent processes. RyR3 predominates in CA1 hippocampal neurons, where it mediates (CICR) essential for synaptic integration and propagation of Ca²⁺ waves during LTP induction. Additionally, RyRs form localized Ca²⁺ nanodomains within dendritic spines, amplifying Ca²⁺ signals to drive activity-dependent plasticity mechanisms. In smooth muscle cells, RyR2 and RyR3 isoforms contribute to vasoregulation by generating elementary Ca²⁺ release events known as Ca²⁺ sparks, which activate large-conductance Ca²⁺-activated K⁺ channels to modulate vascular tone. These sparks arise from clustered RyRs in the sarcoplasmic reticulum, providing localized Ca²⁺ elevations that influence vasoconstriction and dilation. RyR3 is the predominant isoform in many vascular smooth muscle types, though its specific contributions remain under investigation due to overlapping functions with RyR2. IP₃ receptors (IP₃Rs) often co-participate in global Ca²⁺ release, integrating with RyR pathways to fine-tune Ca²⁺ signaling for vasoregulatory responses. In non-excitable cells, RyRs mediate ER Ca²⁺ release to support diverse signaling pathways, such as in oocytes where expressed RyR1 can substitute for IP₃Rs to induce intracellular Ca²⁺ mobilization upon activation. In secretory cells like pancreatic β-cells, RyRs amplify cytosolic Ca²⁺ signals at low expression levels, coupling ER release to insulin secretion and glucose-stimulated responses. This CICR mechanism ensures context-dependent Ca²⁺ waves that regulate exocytosis without requiring high RyR density. Emerging research highlights RyR involvement in immune cells, where low-level expression supports release; for instance, RyR activation in B-lymphocytes and T cells triggers Ca²⁺-dependent inflammatory responses. In mast cells, RyRs drive intracellular Ca²⁺ liberation to modulate and pseudo-allergic reactions, underscoring their role in immune signaling.

Associated Proteins and Regulation

Modulatory Proteins

The FK506-binding proteins (FKBPs), specifically FKBP12 (also known as calstabin1) and FKBP12.6 (calstabin2), serve as key modulatory proteins for ryanodine receptors (RyRs). FKBP12 binds tightly to RyR1 in skeletal muscle, stabilizing the channel in a closed state and reducing its open probability to prevent aberrant calcium leaks during resting conditions. This binding occurs at a 1:1 stoichiometry per RyR monomer, with dissociation promoted under conditions of oxidative stress or hyperphosphorylation, leading to increased channel activity and diastolic calcium release. Similarly, FKBP12.6 associates with RyR2 in cardiac muscle, where it inhibits spontaneous channel openings and maintains coupled gating, thereby ensuring synchronized calcium release during excitation-contraction coupling. Dissociation of FKBP12.6 from RyR2 has been proposed to be triggered by protein kinase A phosphorylation at serine 2808, heightening the channel's sensitivity to luminal calcium and contributing to arrhythmogenic leaks under stress, though this mechanism remains debated in the literature. Triadin and junctin are integral sarcoplasmic reticulum (SR) proteins that anchor RyRs to calsequestrin, facilitating luminal calcium sensing and modulating release dynamics. Triadin, a transmembrane protein with multiple isoforms, directly interacts with RyR1 and RyR3 in skeletal muscle, forming a macromolecular complex that links the calcium-binding protein calsequestrin to the channel's luminal domain. This interaction enhances the RyR's responsiveness to SR calcium load, promoting coordinated release while inhibiting premature openings at low luminal calcium levels. Junctin, structurally related to triadin, binds both RyR and calsequestrin independently of calcium concentration, stabilizing the junctional complex and tuning RyR gating to luminal calcium variations through allosteric regulation. Together, these proteins ensure efficient calcium buffering and release by integrating SR luminal conditions with channel activity. In skeletal muscle, the alpha1 subunit of the dihydropyridine receptor (DHPR) acts as a direct physical coupler to RyR1, enabling excitation-contraction coupling without requiring calcium influx. The II-III loop of the DHPR alpha1S isoform forms a critical interaction site with the RyR1 N-terminal domain, transmitting conformational changes from membrane depolarization to trigger channel opening. This tetrad arrangement positions four DHPRs opposite every other RyR1, ensuring precise bidirectional signaling where RyR1 enhances DHPR clustering in return. Phospholamban provides indirect modulation of RyR activity by regulating the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), which influences SR calcium loading and thus luminal sensing by the receptor. In its unphosphorylated state, phospholamban inhibits SERCA2a, reducing calcium uptake and lowering SR stores, which in turn decreases RyR open probability through luminal feedback. Phosphorylation of phospholamban at serine 16 by protein kinase A relieves this inhibition, boosting SERCA activity and elevating luminal calcium to heighten RyR sensitivity during sympathetic stimulation. This mechanism integrates global calcium homeostasis with RyR function, primarily in cardiac and slow skeletal muscle.

Endogenous Regulators

The ryanodine receptor (RyR) exhibits biphasic regulation by cytosolic Ca²⁺, where low micromolar concentrations (1-10 μM) activate the channel to facilitate Ca²⁺-induced Ca²⁺ release, while higher concentrations (>100 μM) lead to inhibition by binding to distinct low-affinity sites. This dual effect ensures precise control of Ca²⁺ release from intracellular stores, preventing excessive efflux. Additionally, luminal Ca²⁺ within the enhances channel sensitivity to cytosolic activators and counteracts high cytosolic Ca²⁺-induced inhibition, thereby supporting sustained release under physiological conditions. Mg²⁺ serves as a key inhibitory regulator of RyR channels, with an IC₅₀ of approximately 1 mM under physiological ionic conditions, primarily by competing with Ca²⁺ at activation sites or binding to inhibitory sites distinct from the Ca²⁺ pore. In contrast, nucleotides such as ATP and Mg-ADP promote channel activation through binding to specific nucleotide sites on the cytosolic domain, increasing open probability and facilitating Ca²⁺ release, particularly in the presence of subactivating Ca²⁺ levels. Acidosis inhibits RyR activity by reducing channel sensitivity to activating Ca²⁺, with protonation of key residues decreasing open probability and contributing to diminished Ca²⁺ release during ischemic conditions. Redox modulation further tunes RyR gating; oxidative stress promotes S-glutathionylation of specific cysteine residues, enhancing channel open probability and Ca²⁺ leak, whereas reducing conditions reverse this effect to stabilize closure. Phosphorylation by (PKA) at serine residue 2808 (and potentially S2030) on RyR2 sensitizes the channel to luminal and cytosolic Ca²⁺, increasing release probability and supporting enhanced contractility during β-adrenergic stimulation, though the precise sites and effects remain subjects of ongoing debate. This integrates signaling pathways to dynamically adjust RyR function in response to physiological demands.

Pharmacology

Channel Modulators

Ryanodine, a plant alkaloid, binds with high affinity (Kd ≈ 10 nM) to the open state of ryanodine receptors (RyRs), locking the channel in a subconductance state that reduces full conductance to approximately 20-50% of the normal open state.35780-5) At low nanomolar concentrations, ryanodine activates RyR channels by stabilizing this partially open conformation, thereby facilitating sustained but reduced Ca²⁺ release; however, at higher micromolar concentrations (>100 μM), it fully inhibits channel activity by promoting closure. This biphasic modulation arises from ryanodine's preferential binding to the open conformation, allosterically altering the channel's gating kinetics across RyR1, RyR2, and RyR3 isoforms. Dantrolene, a hydantoin derivative used as a relaxant, inhibits Ca²⁺ release primarily through RyR1 by binding to a specific site in the N-terminal region, reducing the channel's sensitivity to activation triggers (IC₅₀ ≈ 120 nM for Ca²⁺ release inhibition in the presence of adenine nucleotides). This inhibition stabilizes the closed state of RyR1, decreasing open probability and attenuating excitation-contraction coupling in , which underlies its therapeutic role in treating by preventing excessive Ca²⁺ efflux. The mechanism involves allosteric interactions that enhance Mg²⁺ inhibition and require the presence of adenine nucleotides and for maximal effect, with minimal impact on RyR2 at clinically relevant doses. Caffeine acts as a positive allosteric modulator of RyRs by binding to a distinct site that increases the channel's sensitivity to cytosolic Ca²⁺, thereby potentiating open probability and promoting Ca²⁺-induced Ca²⁺ release at concentrations of 1-10 mM. This sensitization lowers the threshold for channel activation without directly opening the pore, effectively amplifying luminal Ca²⁺-dependent gating and enhancing the frequency and amplitude of Ca²⁺ sparks in both skeletal (RyR1) and cardiac (RyR2) muscle. The allosteric effect involves conformational changes that couple the caffeine-binding domain to the Ca²⁺ activation sites, facilitating cooperative gating across RyR isoforms. Ruthenium red, a polycationic dye, serves as a potent pore blocker of RyRs, inhibiting Ca²⁺ flux by binding within the ion conduction pathway and occluding the channel lumen (IC₅₀ ≈ 100 nM). This blockade reduces unitary conductance and prevents permeation of divalent cations, effectively silencing RyR-mediated Ca²⁺ release in a voltage-independent manner across RyR1 and RyR2 isoforms. The interaction involves multiple binding sites along the pore, leading to a use-dependent inhibition that is particularly useful for dissecting RyR contributions to Ca²⁺ signaling in isolated systems.

Insecticidal Agents

Ryanodine, a diterpenoid alkaloid extracted from the roots and stems of the South American plant Ryania speciosa (Vahl) Baill., served as an early botanical insecticide against lepidopteran and hemipteran pests, with its insecticidal activity first documented in 1946. This compound binds to insect ryanodine receptors (RyRs) with high affinity, locking the channels in a prolonged open state that disrupts calcium homeostasis, leading to muscle paralysis and death. Although ryanodine exhibits toxicity to mammals due to similar binding affinity for mammalian RyRs, its use declined after the 1980s owing to low potency and replacement by synthetic alternatives. Modern insecticidal agents targeting insect RyRs primarily include diamide insecticides, introduced in the late 2000s, which activate these channels selectively in pests while exhibiting low toxicity to mammals and beneficial insects. Representative examples are chlorantraniliprole (an anthranilic diamide) and flubendiamide (a phthalic diamide), both classified under Insecticide Resistance Action Committee (IRAC) Group 28 for their shared mode of action. These compounds bind to a specific site in the pseudo-voltage sensing domain (pVSD) of insect RyRs, stabilizing the open conformation and causing massive, unregulated Ca²⁺ release from the sarcoplasmic reticulum into the cytoplasm. This Ca²⁺ overload triggers hypercontraction of muscles, cessation of feeding, paralysis, and eventual insect death, typically within hours of exposure. The selectivity of diamides for insect RyRs over mammalian counterparts arises from structural differences, particularly species-specific residues in the pVSD and central pore region, such as isoleucine at position 4790 in lepidopteran RyRs (versus methionine in mammals), which enhance binding affinity by 100- to 1,000-fold in insects. For instance, chlorantraniliprole has an EC₅₀ of approximately 17 nM for activating wild-type diamondback moth (Plutella xylostella) RyR but requires micromolar concentrations for mammalian RyR1. This specificity minimizes off-target effects, contributing to the environmental safety of diamides in integrated pest management (IPM) programs. Resistance to diamide insecticides has emerged in lepidopteran pests like Spodoptera frugiperda and P. xylostella, primarily through point mutations in the RyR gene that alter the binding site and reduce insecticide efficacy. Key mutations include G4946E in the S6 helix and I4790M/K in the pVSD, which can confer resistance ratios exceeding 2,000-fold by decreasing binding affinity and impairing channel gating. These genetic changes, often recessive and associated with fitness costs like reduced reproduction, have spread globally via gene flow and intensive agricultural use, prompting resistance monitoring and rotation strategies to sustain diamide effectiveness and mitigate broader environmental risks from escalating pesticide applications.

Role in Disease

Skeletal Muscle Disorders

Skeletal muscle disorders associated with ryanodine receptor 1 (RyR1) dysfunction primarily arise from in the RYR1 gene, which encodes the Ca²⁺ release channel essential for excitation-contraction coupling in fibers. These disorders include susceptibility, central core disease, and multiminicore disease, each characterized by distinct mutational mechanisms leading to aberrant Ca²⁺ handling. Over 400 RYR1 variants have been identified across these conditions, highlighting the . Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by volatile anesthetics or succinylcholine, resulting in a life-threatening hypermetabolic crisis due to uncontrolled Ca²⁺ release from the sarcoplasmic reticulum. Gain-of-function mutations in RYR1, such as the R614C variant (p.Arg614Cys), hypersensitize the channel to activators like caffeine and halothane, causing a massive Ca²⁺ storm that leads to muscle rigidity, tachycardia, hypercapnia, and potentially fatal hyperthermia. The prevalence of MH susceptibility is estimated at 1:2000 to 1:10,000 individuals in the general population, with RYR1 mutations accounting for the majority of cases. Central core disease (CCD) manifests as a congenital with proximal , , and delayed motor development, often evident from infancy. Hypomorphic RYR1 mutations, typically autosomal dominant and located in the C-terminal region, reduce channel expression or impair Ca²⁺ release, leading to excitation-contraction uncoupling and the formation of central cores—pale, unstructured regions devoid of oxidative enzymes in type I muscle fibers. These mutations are responsible for over 90% of typical CCD cases, with histological cores confirming the diagnosis. Multiminicore disease (MmD), another RYR1-related congenital , features multiple small cores or minicores in muscle fibers, accompanied by axial , respiratory insufficiency, and external ophthalmoplegia. Primarily caused by autosomal recessive hypomorphic mutations that diminish RyR1 protein levels and Ca²⁺ release capacity, MmD can also occur in autosomal dominant forms with specific variants; these lead to mitochondrial depletion and disrupted organization within the cores. Approximately 50% of MmD cases are linked to RYR1 mutations, often overlapping with other congenital myopathies.

Cardiac and Neurological Conditions

Mutations in the RYR2 gene, which encodes the ryanodine receptor type 2 (RyR2), are a primary cause of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited arrhythmia syndrome characterized by stress-induced bidirectional or polymorphic ventricular tachycardia. These mutations often result in leaky RyR2 channels, leading to spontaneous diastolic calcium release from the sarcoplasmic reticulum during sympathetic stimulation, which triggers delayed afterdepolarizations and arrhythmias. For instance, the R4496C mutation in RyR2 has been shown in knock-in mouse models to cause calcium leak under catecholaminergic stress, recapitulating the CPVT phenotype with exercise-induced ventricular tachycardia. Approximately 60% of CPVT cases are linked to RYR2 mutations, highlighting their prevalence and the role of aberrant calcium handling in disease pathogenesis. RyR2 variants have also been associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), a desmosomal disorder involving fibrofatty replacement of the right ventricular myocardium and ventricular arrhythmias. Rare RYR2 variants occur in about 9% of ARVC probands, contributing to calcium mishandling that exacerbates arrhythmogenesis and structural remodeling. Specific examples include mutations such as R176Q, L433P, N2386I, and T2504M, identified in ARVC families without desmosomal gene variants, where they promote diastolic calcium leaks similar to those in CPVT but manifest with a conventional ARVC phenotype including right ventricular dilation. However, some evidence suggests overlap with CPVT phenotypes, prompting reclassification of certain RYR2 variants away from primary ARVC causation. In neurological conditions, RyR2 hyperactivation plays a key role in Alzheimer's disease (AD) pathology, particularly in the hippocampus where it drives neuronal hyperactivity and calcium dysregulation. Soluble amyloid-β (Aβ) oligomers enhance RyR2-mediated calcium release from the endoplasmic reticulum, increasing the open probability of the channel and leading to excessive intracellular calcium elevations in CA1 pyramidal neurons. This hyperactivation contributes to early synaptic dysfunction, network hyperexcitability, and memory impairment, as observed in AD mouse models like 5xFAD, where RyR2 stabilization with dantrolene or carvedilol reduces Aβ-induced hyperactivity without altering plaque load. Key studies demonstrate that limiting RyR2 open time via the E4872Q mutation prevents hippocampal hyperactivity, neuronal loss, and cognitive deficits in these models, underscoring Aβ-RyR2 interactions as a therapeutic target. RyR3 dysfunction is implicated in through disruptions in , where altered expression affects function and motor coordination. In ataxic mouse models, such as rolling mice Nagoya, RyR3 expression is differentially downregulated in the , leading to impaired and deficits that contribute to ataxic symptoms. Rare variants in RYR3 may exacerbate these effects by perturbing intracellular calcium in cerebellar neurons, potentially linking to spinocerebellar ataxias via aberrant calcium handling, though direct causative mutations remain sparsely documented.

Therapeutic Targeting

Established Drug Targets

Dantrolene is the primary established therapeutic agent targeting ryanodine receptors (RyRs), specifically approved for the treatment of malignant hyperthermia (MH), a life-threatening reaction triggered by volatile anesthetics in susceptible individuals. Administered intravenously, dantrolene acts as a postsynaptic muscle relaxant by directly inhibiting RyR1 channels in skeletal muscle, thereby blocking excessive calcium release from the sarcoplasmic reticulum and terminating the hypermetabolic crisis characteristic of MH. This mechanism stabilizes the RyR1 channel in its closed state, preventing the sustained contracture and hyperthermia associated with the condition. The U.S. Food and Drug Administration (FDA) approved dantrolene sodium for MH in 1979, and it remains the only specific antidote, with rapid IV dosing recommended at 2.5 mg/kg to achieve therapeutic levels during acute episodes. In the management of catecholaminergic polymorphic ventricular tachycardia (CPVT), a genetic arrhythmia linked to RyR2 mutations, flecainide serves as an adjunctive therapy through its off-target inhibition of RyR2 channels. This class Ic antiarrhythmic agent reduces diastolic calcium leak from the sarcoplasmic reticulum by directly binding to and stabilizing open RyR2 channels, thereby suppressing spontaneous calcium waves that trigger ventricular arrhythmias during adrenergic stress. Flecainide is typically administered orally in combination with beta-blockers for patients with breakthrough events on monotherapy, demonstrating efficacy in preventing sudden cardiac death in CPVT without primary effects on sodium channels contributing to its antiarrhythmic action in this context. Beta-blockers, such as nadolol, provide indirect modulation of RyR2 in CPVT and related arrhythmias by attenuating protein kinase A (PKA)-mediated phosphorylation of the receptor. Non-selective beta-adrenergic antagonists like nadolol block catecholamine-induced activation of the beta-adrenergic pathway, reducing PKA activity and subsequent hyperphosphorylation of RyR2 at sites like Ser2808, which stabilizes the channel and decreases calcium leak propensity. Nadolol is preferred over beta1-selective agents due to its superior efficacy in preventing arrhythmic events, administered at doses of 1-2 mg/kg/day as first-line pharmacotherapy. For diagnosing MH susceptibility, the caffeine-halothane contracture test (CHCT) remains the gold standard, assessing functional abnormalities in RyR1 from biopsied skeletal muscle. This in vitro assay exposes muscle fibers to varying concentrations of halothane (0.44-3%) and caffeine (2-32 mM), measuring contracture responses; abnormal hypersensitivity indicates MH risk due to enhanced RyR1 sensitivity. Performed in specialized laboratories, the CHCT confirms genetic predispositions linked to RyR1 variants, guiding anesthetic precautions.

Emerging Therapies

Recent research has identified the Rycals, a class of small-molecule compounds such as S107 and ARM210, as promising stabilizers of ryanodine receptors (RyRs) by promoting the binding of calstabin proteins (FKBP12 to RyR1 and FKBP12.6 to RyR2), which reduces aberrant calcium leakage from the sarcoplasmic reticulum in various disease states. These agents shift RyRs from a leaky, primed state to a closed conformation, preserving sarcoplasmic reticulum calcium stores and improving excitation-contraction coupling. In preclinical models of heart failure, Duchenne muscular dystrophy, and cancer-associated muscle weakness, Rycals have enhanced cardiac and skeletal muscle function without significant off-target effects. S107, in particular, has demonstrated therapeutic potential in mitigating chemotherapy-induced cognitive impairment (chemobrain) by counteracting RyR2 hyperphosphorylation, oxidation, and nitrosylation induced by agents like doxorubicin and methotrexate, thereby preventing calstabin2 dissociation and calcium dysregulation in neuronal cells. In mouse models of breast cancer and non-cancer conditions, S107 treatment preserved cognitive performance and reduced RyR2 leakiness, suggesting its applicability to neurocognitive deficits in cancer survivors. Similarly, ARM210 completed phase 1b clinical trials for RyR1-related myopathies in 2024, where it improved muscle strength in patients, and as of 2025, is undergoing phase 2 evaluation for CPVT at institutions like Mayo Clinic. Xanthine derivatives, including allopurinol and novel 4-oxopyrimidine-based compounds, represent another emerging strategy by acting as RyR agonists that increase channel calcium sensitivity and enhance twitch force in skeletal and cardiac muscles. Cryo-electron microscopy studies have elucidated their binding motifs on RyR1 and RyR2, confirming activation of calcium release without excessive leakage, as evidenced by increased ryanodine binding and force generation in mouse extensor digitorum longus muscles (e.g., caffeine enhanced force by approximately 3 N/cm²). These agents hold promise for treating age-related sarcopenia and heart failure, where RyR hypo-function contributes to muscle weakness, potentially repurposing allopurinol beyond its xanthine oxidase inhibitory role. Additional investigational approaches include selective RyR2 inhibitors like EL20, a tetracaine derivative that reduces open probability in calmodulin-dissociated channels without proarrhythmic risks, showing efficacy in preclinical arrhythmia models. Carvedilol analogs such as VK-II-86 suppress store-overload-induced calcium release in CPVT and heart failure without inducing bradycardia, offering improved specificity over the parent β-blocker. Gene therapy strategies, including vectors that enhance calmodulin binding to RyR2, have attenuated hypertrophy in pressure-overload mouse models, highlighting potential for mutation-specific interventions in RyR-associated cardiomyopathies. Overall, these therapies underscore RyRs as viable targets, with ongoing preclinical and early-phase trials emphasizing disease-modifying potential across cardiac, muscular, and neurological disorders.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2964179/
  2. https://doi.org/10.1038/331315a0
  3. https://doi.org/10.1146/annurev.ph.56.030194.002413
  4. https://doi.org/10.1172/JCI162891
  5. https://pubmed.ncbi.nlm.nih.gov/1079008/
  6. https://www.jbc.org/article/S0021-9258(18)49303-9/fulltext
  7. https://www.nature.com/articles/339439a0
  8. https://www.nature.com/articles/333315a0
  9. https://pubs.acs.org/doi/10.1021/acscentsci.6b00361
  10. https://www.sciencedirect.com/topics/medicine-and-dentistry/ryanodine
  11. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ryanodine
  12. https://www.sciencedirect.com/topics/immunology-and-microbiology/ryanodine-receptor
  13. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ryanodine-receptor
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5192967/
  15. https://www.sciencedirect.com/science/article/pii/S0167488918301848
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC8741649/
  17. https://rupress.org/jgp/article/149/12/1065/43566/The-structural-basis-of-ryanodine-receptor-ion
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4338550/
  19. https://www.sciencedirect.com/science/article/pii/S096921261300213X
  20. https://www.nature.com/articles/ncomms2501
  21. https://www.pnas.org/doi/10.1073/pnas.2122140119
  22. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.897494/full
  23. https://www.nature.com/articles/cr201689
  24. https://www.nature.com/articles/ncomms8947
  25. https://pubs.acs.org/doi/10.1021/acs.jpclett.1c00681
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4052289/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC5715910/
  28. https://www.sciencedirect.com/science/article/pii/S0021925820435094
  29. https://www.ncbi.nlm.nih.gov/gene/6261
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4738161/
  31. https://ghr.nlm.nih.gov/gene/RYR1
  32. https://www.ncbi.nlm.nih.gov/omim/180901
  33. https://www.pnas.org/doi/10.1073/pnas.1115111108
  34. https://doi.org/10.1016/j.ceca.2006.10.007
  35. https://pubmed.ncbi.nlm.nih.gov/17118445/
  36. https://www.ncbi.nlm.nih.gov/gene/6262
  37. https://www.proteinatlas.org/ENSG00000198626-RYR2
  38. https://www.ncbi.nlm.nih.gov/gene/6263
  39. https://www.uniprot.org/uniprotkb/Q15413/entry
  40. https://www.nature.com/articles/s41467-024-52998-9
  41. https://www.pnas.org/doi/10.1073/pnas.032657599
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC7040155/
  43. https://doi.org/10.1038/369556a0
  44. https://www.science.org/doi/10.1126/sciadv.adl1126
  45. https://journals.physiology.org/doi/full/10.1152/physrev.00013.2002
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2214709/
  47. https://www.sciencedirect.com/science/article/pii/S1550413111002555
  48. https://rupress.org/jgp/article/141/5/567/43221/Comparison-of-myoplasmic-calcium-movements-during
  49. http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602004000400012
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3023997/
  51. https://www.science.org/doi/10.1126/science.8235594
  52. https://www.pnas.org/doi/10.1073/pnas.0602133103
  53. https://portlandpress.com/biochemj/article/396/1/7/41631/Ser-2030-but-not-Ser-2808-is-the-major
  54. https://rupress.org/jgp/article/151/2/131/120429/Phosphorylation-of-the-ryanodine-receptor-2-at
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC8379958/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC7304577/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC4476683/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC6930021/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC5439506/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC2531252/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC5866223/
  62. https://pubmed.ncbi.nlm.nih.gov/8612969/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12109991/
  64. https://pubmed.ncbi.nlm.nih.gov/15033925/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3730249/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10315577/
  67. https://pubmed.ncbi.nlm.nih.gov/7693682/
  68. https://pubmed.ncbi.nlm.nih.gov/10830164/
  69. https://www.ahajournals.org/doi/10.1161/01.res.0000115945.89741.22
  70. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043817
  71. https://www.sciencedirect.com/science/article/pii/S000634950474271X
  72. https://pubmed.ncbi.nlm.nih.gov/17515962/
  73. https://pubs.acs.org/doi/10.1021/bi0267689
  74. https://pubmed.ncbi.nlm.nih.gov/9826602/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6082316/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC2270229/
  77. https://www.sciencedirect.com/science/article/pii/S0021925820768729
  78. https://www.pnas.org/doi/10.1073/pnas.0510113103
  79. https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/JP286453
  80. https://www.jci.org/articles/view/32726
  81. https://doi.org/10.1074/jbc.M006104200
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC2747660/
  83. https://pubmed.ncbi.nlm.nih.gov/7510773/
  84. https://www.nature.com/articles/srep14680
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC11491487/
  86. https://www.sciencedirect.com/science/article/abs/pii/S0048357525003426
  87. https://www.nature.com/articles/s41598-021-82024-7
  88. https://pubmed.ncbi.nlm.nih.gov/1510267/
  89. https://skeletalmusclejournal.biomedcentral.com/articles/10.1186/s13395-020-00243-4
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC7183298/
  91. https://academic.oup.com/brain/article/129/6/1470/296351
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC7783440/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC6277304/
  94. https://thejcn.com/DOIx.php?id=10.3988/jcn.2008.4.3.123
  95. https://pubmed.ncbi.nlm.nih.gov/16825580/
  96. https://pubmed.ncbi.nlm.nih.gov/29477366/
  97. https://pubmed.ncbi.nlm.nih.gov/25041964/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC5063271/
  99. https://www.ahajournals.org/doi/10.1161/CIRCGEN.120.003273
  100. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532726/
  101. https://doi.org/10.1016/j.celrep.2020.108169
  102. https://pubmed.ncbi.nlm.nih.gov/18313230/
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC4433580/
  104. https://www.ncbi.nlm.nih.gov/books/NBK535398/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC7754833/
  106. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.316819
  107. https://pubmed.ncbi.nlm.nih.gov/33297863/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC2862146/
  109. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056018
  110. https://pubmed.ncbi.nlm.nih.gov/2064058/
  111. https://emedicine.medscape.com/article/2231150-workup
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC9843046/
  113. https://www.science.org/doi/10.1126/scitranslmed.adf8977
  114. https://forbion.com/news-insights/news/armgo-pharma-publishes-positive-phase-1b-trial-results-of-rycal-arm210-for-the-treatment-of-ryanodine-receptor-1-related-myopathies/
  115. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.075150
  116. https://www.pnas.org/doi/10.1073/pnas.2422082122
  117. https://www.mdpi.com/1422-0067/23/8/4435
Add your contribution
Related Hubs
User Avatar
No comments yet.